Evidence map›Paper›PMID 22293568›Full record

ReviewNature reviews. Drug discovery2012

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy.

Mark J Millan, Yves Agid, Martin Brüne, Edward T Bullmore, Cameron S Carter, Nicola S Clayton, Richard Connor, Sabrina Davis, Bill Deakin, Robert J DeRubeis and 15 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Drug discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 566 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
566citing papers in PubMed, 6 pooled it
21.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

566 citing papers in PubMed, 6 syntheses or guidelines pooled it, 1,271 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Role of 5-HTBiomolecules · 2025
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. 5-HTBiological psychiatry. Cognitive neuroscience and neuroimaging · 2023
    Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

506 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 7 countries.

Mark J MillanInstitut de Recherche Servier, 78290 Croissy/Seine, France. mark.millan@fr.netgrs.com
Yves Agid
Martin Brüne
Edward T Bullmore
Cameron S Carter
Nicola S Clayton
Richard Connor
Sabrina Davis
Bill Deakin
Robert J DeRubeis
Bruno Dubois
Mark A Geyer
Guy M Goodwin
Philip Gorwood
Thérèse M Jay
Marian Joëls
Isabelle M Mansuy
Andreas Meyer-Lindenberg
Declan Murphy
Edmund Rolls
Bernd Saletu
Michael Spedding
John Sweeney
Miles Whittington
Larry J Young
AVL (France) · FRCentre National de la Recherche Scientifique · FREmory University · USGlaxoSmithKline (United Kingdom) · GBHeidelberg University · DEInserm · FRInstitut de Psychiatrie et Neurosciences de Paris · FRInstitut du Cerveau · FRKing's College London · GBMedical University of Vienna · ATNewcastle University · GBRuhr University Bochum · DEServier (France) · FRSorbonne Université · FRThe University of Texas Southwestern Medical Center · USUniversity Medical Center Utrecht · NLUniversity of California, Davis · USUniversity of California, San Diego · USUniversity of Cambridge · GBUniversity of Manchester · GB

Funding

Department of Health RP-PG-0606-1045Medical Research Council G0400061
6 · The paper itself

Abstract

Studies of psychiatric disorders have traditionally focused on emotional symptoms such as depression, anxiety and hallucinations. However, poorly controlled cognitive deficits are equally prominent and severely compromise quality of life, including social and professional integration. Consequently, intensive efforts are being made to characterize the cellular and cerebral circuits underpinning cognitive function, define the nature and causes of cognitive impairment in psychiatric disorders and identify more effective treatments. Successful development will depend on rigorous validation in animal models as well as in patients, including measures of real-world cognitive functioning. This article critically discusses these issues, highlighting the challenges and opportunities for improving cognition in individuals suffering from psychiatric disorders.

Indexed as

BrainCognitionCognition DisordersEpigenesis, GeneticGenetic Predisposition to DiseaseHumansMagnetic Resonance ImagingMental DisordersNeuropsychological TestsNootropic AgentsPsychomotor PerformanceRisk FactorsStress, PsychologicalNootropic Agents

Identifiers

PMID22293568
OpenAlexW2080092700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.